Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the appearance of disease phenotypes or in advanced stages of disease in the YAC128 m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Garcia-Miralles, Marta, Geva, Michal, Tan, Jing Ying, Yusof, Nur Amirah Binte Mohammad, Cha, Yoonjeong, Kusko, Rebecca, Tan, Liang Juin, Xu, Xiaohong, Grossman, Iris, Orbach, Aric, Hayden, Michael R., Pouladi, Mahmoud A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2017
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5752291/
https://ncbi.nlm.nih.gov/pubmed/29212949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.95665
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia